Croda shares fall on weaker cash Flow despite in-line profit, reaffirmed outlook

Published 29/07/2025, 10:36
© Reuters.

Investing.com -- Shares of Croda International (LON:CRDA) fell more than 4% on Tuesday after the company reported weaker cash flow and rising debt in its first-half 2025 results, despite posting profit in line with analyst expectations and maintaining full-year guidance.

The specialty chemicals company reported adjusted profit before tax of £138 million for the first half of 2025, slightly above Jefferies’ estimate of £136 million and the consensus forecast of £137 million. 

Group sales for the second quarter were £414 million, matching Jefferies’ forecast and just below the £415 million consensus, reflecting 6% year-over-year growth at constant currency.

Adjusted EBIT for the first half was £147 million, down 1% from the consensus estimate of £149 million. 

However, EBIT margins improved by 50 basis points compared to the prior year period.

Croda reiterated its full-year 2025 constant currency adjusted PBT guidance of £265 million to £295 million. 

After accounting for an updated foreign exchange headwind of approximately £9.5 million, the revised PBT range stands at £255 million to £285 million. 

This compares with Jefferies’ forecast of £271 million and a consensus estimate of £272 million.

“With 1H25 Adj PBT tracking marginally ahead of expectations, yet an uncertain macro backdrop persists, we foresee limited net changes to FY25 Adj PBT Cons of £273.5m,” said analysts at Morgan Stanley (NYSE:MS) in a note.

The company announced an additional £60 million in cost savings, bringing its total planned efficiency program to £100 million by the end of 2027.

By division, Life Sciences outperformed expectations, while Consumer Care fell slightly below forecasts. 

Consumer Care’s second-quarter growth was 30 basis points ahead of consensus.

First-half adjusted EBIT for Consumer Care was £86 million, 6% below Jefferies’ estimate of £91 million and 2% below the consensus of £88 million. 

Life Sciences reported adjusted EBIT of £56 million, 4% above Jefferies’ estimate and 2% above consensus. 

EBIT margins in the division rose by 320 basis points year-over-year. PTIC/Industrial Specialties recorded adjusted EBIT of £5 million, ahead of Jefferies’ estimate of £4 million and slightly below the £6 million consensus.

Operating cash flow for the first half was £96.5 million, down sharply from £194.5 million a year earlier, primarily due to working capital outflows.

Free cash flow declined to £34.2 million from £122.7 million. Net debt rose to £580 million, equivalent to 1.5 times EBITDA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.